Designing a recombinant Bacmid construct of HCV core+1 in Baculovirus expression system
,
Abstract
Background and Objectives: Hepatitis C virus (HCV) chronically infects around 200 million people worldwide and fre- quently causes liver cirrhosis and hepatocellular carcinoma. Rapid detection of this virus results in decreasing the distance between infection and initiation the anti-viral treatment, and may prevent most of the undesirable consequences. The new detected HCV protein "Core+1" made from the ribosomal frame shift in Core region is an important candidate for diagnostic tools. This study was conducted to design a recombinant Bacmid plasmid expressing the HCV 1a Core+1 sequence in the Baculovirus expression system for further diagnostic applications.
Materials and Methods: The HCV Core +1 gene was amplified by PCR using the pcDNA-HAF recombinant vector that contained the Core+1 sequence from HCV genotype 1a as a template, and the specific primers with 2 restriction sites for Nco I and Xba I restriction enzymes. The PCR product was cloned in XbaI/NcoI restriction sites of the linearized pFastBac-HTB vector and evaluated by using those restriction enzymes and sequencing. Then the recombinant pFastBac-HTB vector was transformed in DH10Bac and the result was screened and confirmed by X-Gal discrimination and PCR.
Results: The HCV 1a Core+1 was successfully amplified and the PCR product was confirmed by using the related restriction enzymes and sequencing. Cloning of pFastBac vector with the purified PCR product of HCV Core+1 was confirmed. Finally, the recombinant Bacmid was successfully transformed in DH10Bac.
Conclusion: The recombinant Bac-Core+1 expression vector is considered as an important tool to transfect the sf9 cell line and expression the Core+1 protein.
Mauger DM, Golden M, Yamane D, Williford S, Lem- on SM, Martin DP, et al. Functionally conserved archi- tecture of hepatitis C virus RNA genomes. Proc Natl Acad Sci U S A 2015; 112: 3692-3697.
Shakeri MT, Nomani H, Ghayour Mobarhan M, Sima HR, Gerayli S, Shahbazi S, et al. The prevalence of hepatitis C virus in mashhad, iran: a population-based study. Hepat Mon 2013; 13: e7723.
Li HC, Ma HC, Yang CH, Lo SY. Production and pathogenicity of hepatitis C virus core gene products. World J Gastroenterol 2014; 20: 7104-7122.
Kotta-Loizou I, Vassilaki N, Pissas G, Kakkanas A, Bakiri L, Bartenschlager R, et al. Hepatitis C virus core+1/ARF protein decreases hepcidin transcription through an AP1 binding site. J Gen Virol 2013; 94:1528-1534.
Komurian-Pradel F, Rajoharison A, Berland JL, Khouri V, Perret M, Van Roosmalen M, et al. Antigen- ic relevance of F protein in chronic hepatitis C virus infection. Hepatology 2004; 40: 900-909.
Vassilaki N, Mavromara P. The HCV ARFP/F/core+1 protein: production and functional analysis of an un- conventional viral product. IUBMB Life 2009; 61: 739-752.
Rehermann B. Pathogenesis of chronic viral hepati-tis: differential roles of T cells and NK cells. Nat Med 2013; 19: 859-868.
Jackson RJ, Hellen CU, Pestova TV. Termination and post-termination events in eukaryotic translation. Adv Protein Chem Struct Biol 2012; 86: 45-93.
Niepmann M. Hepatitis C virus RNA translation. Curr Top Microbiol Immunol 2013; 369: 143-166.
Hashempour T AM, Bamdad T, Merat S, Zaer-Rezaee H, Fakharzadeh E, et al. Development of a recombi- nant based ELISA using specific antibodies to F pro- tein in HCV chronically infected patients-A seroprev- alence study. Iranian Journal of Virology 2010; 4: 1-6.
Cohen M, Bachmatov L, Ben-Ari Z, Rotman Y, Tur-Kaspa R, Zemel R. Development of specific an- tibodies to an ARF protein in treated patients with chronic HCV infection. Dig Dis Sci 2007; 52: 2427-2432.
Yue M, Deng X, Zhai X, Xu K, Kong J, Zhang J, et al.Th1 and Th2 cytokine profiles induced by hepatitis C virus F protein in peripheral blood mononuclear cells from chronic hepatitis C patients. Immunol Lett 2013;152: 89-95.
Assenberg R, Wan PT, Geisse S, Mayr LM. Advances in recombinant protein expression for use in pharma- ceutical research. Curr Opin Struct Biol 2013; 23: 393-402.
LaVallie ER, McCoy JM. Gene fusion expression sys- tems in Escherichia coli. Curr Opin Biotechnol 1995;6: 501-506.
Gao DY, Zhang XX, Hou G, Jin GD, Deng Q, Kong XF, et al. Assessment of specific antibodies to F pro- tein in serum samples from Chinese hepatitis C pa- tients treated with interferon plus ribavarin. J Clin Microbiol 2008; 46: 3746-3751.
Kost TA, Condreay JP, Ames RS. Baculovirus gene delivery: a flexible assay development tool. Curr Gene Ther 2010; 10: 168-173.
Trowitzsch S, Bieniossek C, Nie Y, Garzoni F, Berger I. New baculovirus expression tools for recombinant protein complex production. J Struct Biol 2010; 172:45-54.
Chuang WC, Allain JP. Differential reactivity of pu-tative genotype 2 hepatitis C virus F protein between chronic and recovered infections. J Gen Virol 2008;89: 1890-1900.
Firth AE, Brierley I. Non-canonical translation in RNA viruses. J Gen Virol 2012; 93: 1385-1409.
Baghbani-arani F, Roohvand F, Aghasadeghi MR, Eidi A, Amini S, Motevalli F, et al. Expression and characterization of Escherichia coli derived hepatitis C virus ARFP/F protein. Mol Biol (Mosk) 2012; 46: 251-259.
Belzhelarskaia SN, Koroleva NN, Popenko VV, Drutsa VL, Orlova OV, Rubtsov PM, et al. [Characterization of hepatitis C virus structural proteins and HCV-like particles produced in recombinant baculovirus infect- ed insect cells]. Mol Biol (Mosk) 2010; 44: 107-119.
| Files | ||
| Issue | Vol 7 No 4 (2015) | |
| Section | Articles | |
| Keywords | ||
| Hepatitis C Virus HCV Core 1 pFastBac vector Bacmid expression vector Baculovirus expression system | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
